Accès à distance ? S'identifier sur le proxy UCLouvain
An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results.
Primary tabs
| Document type | Communication à un colloque (Conference Paper) – Abstract, Présentation orale avec comité de sélection |
|---|---|
| Publication date | 2004 |
| Language | Anglais |
| Conference | "40th Annual Meeting of the American-Society-of-Clinical-Oncology", New Orleans (La) (Jun 05-08, 2004) |
| Journal information | "Journal of Clinical Oncology" - Vol. 22, no. 14, p. 248S-248S (2004) |
| Peer reviewed | yes |
| issn | 0732-183X |
| e-issn | 1527-7755 |
| Publisher | Amer Soc Clinical Oncology (Alexandria) |
| Affiliations |
UCL
- Cliniques universitaires Saint-Luc UCL - MD/MINT - Département de médecine interne |
| Links |
| Bibliographic reference | Tabernero, JM ; Humblet, Yves ; Van Cutsem, E. ; Sastre, J. ; Cervantes, A. ; et. al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results..40th Annual Meeting of the American-Society-of-Clinical-Oncology (New Orleans (La), Jun 05-08, 2004). In: Journal of Clinical Oncology, Vol. 22, no. 14, p. 248S-248S (2004) |
|---|---|
| Permanent URL | http://hdl.handle.net/2078.1/61074 |